Adamis Pharmaceuticals Corporation company was founded in 2006 and is based in Del Mar, California. Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company’s wholly owned subsidiary, Biosyn, Inc. has a portfolio of product candidates known as microbicides. Biosyn’s product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally. Biosyn’s product candidates include Savvy, which underwent Phase III clinical trials in Ghana and Nigeria for reduction in the transmission of human immunodeficiency virus/acquired immunodeficiency disease, (HIV/AIDS). Effective April 1, 2009, Cellegy Pharmaceuticals, Inc. merged with Adamis Pharmaceuticals Corporation, pursuant to which Adamis Pharmaceuticals Corporation (Adamis) became a wholly owned subsidiary of the Company.

Ipsen develops pharmaceutical products that target oncology, endocrinology, and neuromuscular disorders. The group additionally markets products to treat gastroenterology, cardiovascular, and cognitive disorders. Ipsen operates research-and-development (R&D) centers in Paris, Boston, Barcelona, and London, which have churned out more than 20 products to the global therapeutic market. Its R&D efforts focus on peptide engineering, protein engineering, medicinal chemistry, and advanced drug delivery. The company markets its products directly as well as through third parties, and has formed strategic development alliances with the likes of Medicis and Applied Biosystems (now part of Life Technologies Corporation).

Caprius, Inc. company owns a majority interest in MCM Environmental Technologies, which provides systems for disposal of medical waste. Its SteriMed system can crush, grind, shred, and mix all types of medical waste, including metal sharps and needles, plastic tubing and IV bags, and glass items. Once this process is complete, MCM's Steri-Cid chemical process disinfects the waste, which can then be discarded as regular waste at as little as 10% of the original volume. MCM manufactures the SteriMed system in Israel; the company distributes parts and supplies from facilities in Israel. Officers and directors, led by Austin W. Marxe and David M. Greenhouse hold about 22% of Caprius.

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is an international specialty pharmaceutical company. The Company’s product portfolio consists of four categories of products: India branded generics, US generics, international branded generics and active pharmaceutical ingredients (API). The products of the Company are prescribed in therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. The products manufactured by the Company include Supatret, Winolap, Donamem, Exmasin, Lenzest, Octride Depot 10, Carcidox, Tyrogef, Cernos depot, Milnorm, Levipil, Exzilor and Macorate. The Company’s subsidiaries include Sun Pharma Global Inc. BVI., Sun Pharma Global-FZE, Sun Pharmaceutical (Bangladesh) Ltd., Sun Pharmaceutical Peru S.A.C. and Sun Farmaceutica Ltda-Brazil. In November 2008, the Company, along with its subsidiaries, completed the acquisition of Chattem Chemicals, Inc.

Galapagos has formed its own archipelago of drugs to treat bone and joint ailments and other diseases. The company uses its proprietary genomic drug-discovery technology to develop medicines to treat rheumatoid arthritis, osteoarthritis, and osteoporosis. Galapagos' pharma services subsidiaryBioFocus DPI offers collaborative drug-discovery services to other pharmaceutical companies. Its drug discovery division works with partners to find, test, and market new drugs. The company's pharmaceutical collaborators include top drugmakers GlaxoSmithKline, Eli Lilly, Merck, and Janssen Pharmaceutica, part of Johnson & Johnson. Galapagos has about 40 projects in its R&D pipeline, most of them through these partnerships.

Amgen Inc. company was founded in 1980 and is based in Thousand Oaks, California. Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. The company has a joint venture with Kirin Holdings Company, Limited to manufacture and market darbepoetin alfa; a co-promotion agreement with Wyeth for marketing and selling of ENBREL; and Johnson & Johnson to commercialize recombinant human erythropoietin as a human therapeutic. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies primarily in the United States, Europe, and Canada.

Jazz Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Palo Alto, California. Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company's marketed products include Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for obsessive compulsive disorder and social anxiety disorder. Its product candidate in Phase III clinical trials comprise JZP-6 for the treatment of fibromyalgia. The company's other product candidates in clinical development comprises JZP-8, an intranasal formulation of clonazepam for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens; JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-7 for the treatment of restless legs syndrome.

Adnexus Therapeutics, Inc. engages in the discovery, development, and commercialization of Adnectins biologics/medicines in the United States. The company’s product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases. Adnexus Therapeutics, Inc. was formerly known as Compound Therapeutics, Inc. and changed its name to Adnexus Therapeutics, Inc. in June 2006. The company was founded in 2002 and is headquartered in Waltham, Massachusetts. As of October 19, 2007, Adnexus Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Co.

Senesco Technologies Inc. company was founded in 1964 and is headquartered in New Brunswick, New Jersey. Senesco Technologies, Inc. (Senesco) is a development-stage biotechnology company. The Company along with its wholly owned subsidiary, Senesco, Inc., is engaged in utilizing its eucaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for inhibition in human health applications to develop approaches to treat inflammatory diseases and cancer. In agricultural applications the Company is developing and licensing Factor 5A, DHS and Lipase to enhance the quality and productivity of fruits, flowers, and vegetables and agronomic crops through the control of cell death, referred to herein as senescence, and growth in plants.

Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania. Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The company's proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.